Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Panc Biomarker Presentation at ASCO GI 18-20 Jan 2024

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 01, 2024 6:42pm

140 Views

Post# 35806359

RE:RE:RE:RE:RE:RE:Panc Biomarker Presentation at ASCO GI 18-20 Jan 2024

•

T-cell receptor (TCR) interaction with major histocompatibility complex–antigen complexes leads to antitumour responses.
•

TCR sequencing analysis allows characterisation of T cells that recognise tumour neoantigens.
•

T-cell clonal revival and clonal replacement potentially underpin immunotherapy responses.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996383/

December 07, 2023 - A review of ONCY's AWARE-1 study translational data presented at this year's SABCS and previous scientific conferences demonstrates that pelareorep treatment, especially in combination with atezolizumab, results in:

- an increase in CelTIL score, which correlates with improved clinical outcomes in breast cancer
- increased CD8+ T cell infiltration into tumors
- the generation and expansion of T cell clones, especially TILs
- the upregulation of tumor PD-L1 expression

These findings confirm that pelareorep remodels the tumor microenvironment and stimulates tumor-directed immune responses, effects we believe are driven by the introduction of pelareorep's double-stranded RNA into cancer cells."